Literature DB >> 24002868

CD27 costimulation contributes substantially to the expansion of functional memory CD8(+) T cells after peptide immunization.

Vadim Y Taraban1, Tania F Rowley, Jonathan P Kerr, Jane E Willoughby, Peter M W Johnson, Aymen Al-Shamkhani, Sarah L Buchan.   

Abstract

Naive T cells require signals from multiple costimulatory receptors to acquire full effector function and differentiate to long-lived memory cells. The costimulatory receptor, CD27, is essential for optimal T-cell priming and memory differentiation in a variety of settings, although whether CD27 is similarly required during memory CD8(+) T-cell reactivation remains controversial. We have used OVA and anti-CD40 to establish a memory CD8(+) T-cell population and report here that their secondary expansion, driven by peptide and anti-CD40, polyI:C, or LPS, requires CD27. Furthermore, antigenic peptide and a soluble form of the CD27 ligand, CD70 (soluble recombinant CD70 (sCD70)), is sufficient for secondary memory CD8(+) T-cell accumulation at multiple anatomical sites, dependent on CD80/86. Prior to boost, resting effector- and central-memory CD8(+) T cells both expressed CD27 with greater expression on central memory cells. Nonetheless, both populations upregulated CD27 after TCR engagement and accumulated in proportion after boosting with Ag and sCD70. Mechanistically, sCD70 increased the frequency of divided and cytolytic memory T cells, conferred resistance to apoptosis and enabled retardation of tumor growth in vivo. These data demonstrate the central role played by CD27/70 during secondary CD8(+) T-cell activation to a peptide Ag, and identify sCD70 as an immunotherapeutic adjuvant for antitumor immunity.
© 2013 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD27; CD70; Memory; T cell; TLR; TNFRSF

Mesh:

Substances:

Year:  2013        PMID: 24002868     DOI: 10.1002/eji.201343579

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-03-17       Impact factor: 7.486

2.  CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen.

Authors:  Kelly A Remedios; Lauren Meyer; Bahar Zirak; Mariela L Pauli; Hong-An Truong; Devi Boda; Michael D Rosenblum
Journal:  J Immunol       Date:  2019-06-17       Impact factor: 5.422

3.  CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Authors:  Han Dong; Nathan A Franklin; Shane B Ritchea; Hideo Yagita; Martin J Glennie; Timothy N J Bullock
Journal:  Eur J Immunol       Date:  2015-11-06       Impact factor: 5.532

Review 4.  T Cell Vaccinology: Beyond the Reflection of Infectious Responses.

Authors:  Nathan D Pennock; Justin D Kedl; Ross M Kedl
Journal:  Trends Immunol       Date:  2016-01-30       Impact factor: 16.687

5.  Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.

Authors:  Si-Ming Wei; Jin-Xuan Fei; Feng Tao; Hang-Li Pan; Qing Shen; Li Wang; Yu-Jia Wu; Li Zhou; Sheng-Xin Zhu; Wei-Bin Liao; Hua Ji; Zhao-Liang Xin
Journal:  Int Surg       Date:  2015-01

6.  Evidence for CD19B-CD8T cell interactions in blood and tissues from patients with GvHD.

Authors:  S Deola; C Cugno; P Comoli; I Guido; L Rubert; M Zecca; D Zanolini; A Follenzi; M Langes; G Negri; M Tauber; I Pusceddu; I Cavattoni; M Svaldi; G U Grigoleit; E Baumeister; E Wang; S Rutella; F M Marincola
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

7.  RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.

Authors:  Sean H Lim; Kim M Linton; Graham P Collins; Joke Dhondt; Joshua Caddy; Liz Rossiter; Karan Vadher; Keira Fines; Laura E Rogers; Diana Fernando; Louise Stanton; Andrew J Davies; Peter W M Johnson; Gareth Griffiths
Journal:  Trials       Date:  2018-11-09       Impact factor: 2.279

8.  PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.

Authors:  Sarah L Buchan; Mohannad Fallatah; Stephen M Thirdborough; Vadim Y Taraban; Anne Rogel; Lawrence J Thomas; Christine A Penfold; Li-Zhen He; Michael A Curran; Tibor Keler; Aymen Al-Shamkhani
Journal:  Clin Cancer Res       Date:  2018-03-07       Impact factor: 12.531

9.  Age-related profiling of DNA methylation in CD8+ T cells reveals changes in immune response and transcriptional regulator genes.

Authors:  Liina Tserel; Raivo Kolde; Maia Limbach; Konstantin Tretyakov; Silva Kasela; Kai Kisand; Mario Saare; Jaak Vilo; Andres Metspalu; Lili Milani; Pärt Peterson
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

Review 10.  New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).

Authors:  Angelika M Starzer; Anna S Berghoff
Journal:  ESMO Open       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.